Estimates from the small number of studies available range from 9.0% to 87.5%. 14--17 Such a wide variation probably reflects the problems present in these studies, which include small sample size, mixes in photocoagulation type and spot size, incorrect field testing techniques and unspecified assessment criteria.
Using standardised treatment technique and field assessment, our study aimed to: (1) establish the risk of failing the UK driving field test after both unilateral or bilateral laser PRP and (2) identify risk factors that predispose to failure.
Patients and methods
Patients eligible for inclusion in the study were diabetics receiving laser PRP for proliferative retinopathy whose visual acuity following treatment was at least 6/12 in the treated eye (or in the better eye if the patient received bilateral treatment), patients being selected by case note review. This level was chosen as a suitable approximation to that required by the DVLA for holding a Group 1 driving licence, which states that' a driver must be able to read a vehicle registration plate at 20.5 m in good daylight '.12 This has been shown to equate to a binocular 
Results
The entry criteria were met by 60 patients. The mean age of the patients was 52.5 years; 57% were male, 43% female. In 59% of patients diabetes was type I (categorised as patients younger at onset, rarely obese, requiring insulin for deficiency believed due to autoimmune disease); in the remaining 41 % it was type II (categorised as patients older at onset, often overweight, not necessarily requiring insulin for deficiency and resistance believed to be of non-autoimmune origin). The mean duration of diabetes was 22.5 years. Peripheral new vessels was the initial indication for PRP in 61 % of patients, disc new vessels in the remaining 39%. At the time of field testing, which was a minimum of 1 month after the last laser treatment, retinopathy was considered stable in 88% of eyes, and these eyes had received a mean of 2810 burns. Additional focal laser treatment had been given to 30% of eyes. Details of the main features of the group are shown in Table 1 .
Failure rates following PRP
Uniocular fields were examined from 86 treated eyes. Of these, 36 (42%) failed. Of 17 uniocular fields of eyes that had received no PRP, 2 (12%) failed. Of the 21 binocular fields in which only one eye had been treated, 1 (5%) failed. Of the 34 binocular fields from patients who had received bilateral treatment, 4 (12%) failed, these patients receiving a mean of 2987 burns per eye. Four of 8 (50%) patients who failed both uniocular field tests passed the binocular test. The minimum visual acuity in the second eye of the patients having a binocular field test was 6/60. The results are summarised in Table 2 .
Examples of fields assessed are shown in Figs. 1 and 2. relation to the number of burns applied. Table 3 summarises the results.
Discussion
It is important that ophthalmologists are able to advise patients on whether laser treatment for proliferative retinopathy may itself jeopardise their licence to drive.
Unfortunately, previous studies have produced contradictory results, with reported failure rates ranging from 9.0% to 87.5% in binocular field tests for those patients having bilateral laser PRP. Such a wide variation probably reflects several factors. For example:
1. In two of the studies an overlay combination of the two uniocular fields was used as a measure of the binocular field. This is unsatisfactory as it fails to recognise the phenomenon of binocular enhancement that has been estimated to improve field sensitivity by about 20%?O severe non-proliferative diabetic retinopathy. In our study, 2 of 17 untreated eyes had sufficient field loss to cause failure; both were in long-standing type I diabetics.
In eyes requiring PRP one might expect visual field abnormalities before treatment to be even more marked. 
